肾透明细胞癌中血管抑制蛋白-1与微血管密度的检测及临床意义

田昊; 吴育栋; 李彦君; 晏滨; 柯炳虎; 尚芝群; 牛远杰

doi:10.13201/j.issn.1001-1420.2015.03.005

肾透明细胞癌中血管抑制蛋白-1与微血管密度的检测及临床意义

- 天津医科大学第二医院泌尿外科, 天津市泌尿外科研究所, 天津市泌尿外科基础医学重点实验室(天津, 300211)

详细信息

通讯作者: 牛远杰,E-mail:yuanjieniu68@hotmail.com

中图分类号: R737.11

收稿日期: 2014-09-04

Detection and clinical significance of Vasohibin-1 and microvessel density in clear cell renal cell carcinoma

- Department of Urology, Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin Key Laboratory of Basic Urology, Tianjin, 300211, China

More Information

Corresponding author: NIU Yuanjie, E-mail: yuanjieniu68@hotmail.com

Received Date: 04 September 2014

摘要

摘要: 目的:探讨肾透明细胞癌内血管抑制蛋白-1(Vasohibin-1,VASH1)以及微血管密度(microvessel density,MVD)检测与肾透明细胞癌患者预后之间的关系。方法:采用免疫组织化学方法半定量测定肾透明细胞癌标本VASH1染色的平均细胞累积光密度(average optical density, AOD),并测定CD34标记的MVD。用Cox回归模型分析患者的临床和病理因素与生存预后之间的关系。结果:肾癌组织中VASH1的AOD为0.0435±0.0178,MVD均值为55±34,两者的表达均与病理分期和肿瘤内的凝固性坏死有显著相关性(P＜0.05)。相关性分析显示VASH1与MVD的表达呈负相关(r=-0.641,P＜0.01)。单因素回归分析证明高VASH1组肾透明细胞癌预后显著差于低VASH1组,差异均有统计学意义(HR=2.96,P＜0.05)。多因素回归分析显示患者年龄、病理分期以及肿瘤内凝固性坏死与患者的总体生存(HR=4.90,P＜0.05;HR=3.08,P＜0.05;HR=3.05,P＜0.05)和无复发生存(HR=3.91,P＜0.05;HR=2.85,P＜0.05;HR=3.24,P＜0.05)呈显著相关性。结论:在肾透明细胞癌中,低VASH1表达提示较好的预后,而患者年龄、病理分期以及肿瘤内凝固坏死是肾透明细胞癌的独立预后因素。此研究仍待前瞻性大规模临床试验的验证。
- 肾细胞癌 /
- 血管抑制蛋白-1 /
- 微血管密度 /
- 预后
Abstract: Objective:To investigate the expression of Vasohibin-1 (VASH1) and microvessel density (MVD) marked with CD34 in clear cell renal cell carcinoma (ccRCC) and analyze their correlations with prognosis.Method:Expressions of VASH1 and CD34 in their tissue samples were detected by immunohistochemical (IHC) staining. For VASH1 assessment, the staining intensity of positive tumor cells were evaluated semi-quantitatively and measured by average optical density (AOD) for further analysis. MVD was counted using Weidner's method. Statistical analysis was performed using SPSS 19.0.Result:The AOD of VASH1 in the 79 cancer tissues was 0.0435±0.0178. The MVD value marked by CD34 in the 79 cancer tissues was (55±34) profiles/HPF. The expression of MVD and VASH1 significantly varied with tumor stages and necrosis presence (P＜0.05). Assessed by Spearman's correlation, the expression of VASH1 was negatively associated with MVD (r=-0.641, P＜0.01). The overall survival (OS) and recurrence-free survival (RFS) in ccRCC patients with high VASH1 expression were significantly worse than those low VASH1 expression (P＜0.05). The multivariate analysis showed that age, tumor stage and necrosis presence were significantly correlated with OS and RFS in ccRCC patients.Conclusion:Lower expression of VASH1 indicates better prognosis of ccRCC. Patients' age, tumor stage and necrosis presence were independent prognostic factors for ccRCC. However, more large-scale, prospective trials are needed to confirm our findings.
- renal cell carcinoma /
- Vasohibin-1 /
- microvessel density /
- prognosis

HTML全文

参考文献(14)

[1]	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[2]	Zubac D P, Bostad L, Kihl B, et al. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival[J]. J Urol, 2009, 182(5): 2144-2149.
[3]	Park J Y, Lee J L, Baek S, et al. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy[J]. Hum Pathol, 2014, 45(7): 1437-44.
[4]	Yuan H X, Zhang J P, Kong W T, et al. Elevated microRNA-185 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in clear cell renal cell carcinoma[J]. Tumour Biol, 2014, 14.
[5]	王忠,刘本春,张元芳,等. 肾细胞癌微血管密度与癌细胞转移的相关性[J]. 临床泌尿外科杂志, 1999, (12): 536-538.
[6]	Zhao G, Yang Y, Tang Y, et al. Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma[J]. Med Oncol, 2012, 29(5): 3325-3334.
[7]	Cheng S H, Liu J M, Liu Q Y, et al. Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis[J]. Int J Clin Exp Pathol, 2014, 7(9): 5855-5863.
[8]	Kerbel R S. Tumor angiogenesis[J]. N Engl J Med, 2008, 358(19): 2039-2049.
[9]	Kitajima T, Toiyama Y, Tanaka K, et al. Vasohibin-1 increases the malignant potential of colorectal cancer and is a biomarker of poor prognosis[J]. Anticancer Res, 2014, 34(10): 5321-5329.
[10]	Hosaka T, Kimura H, Heishi T, et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis[J]. Am J Pathol, 2009, 175(1): 430-439.
[11]	Kosaka T, Miyazaki Y, Miyajima A, et al. The prognostic significance of vasohibin-1 expression in patients with prostate cancer[J]. Br J Cancer, 2013, 108(10): 2123-2129.
[12]	Verheul H M, van Erp K, Homs M Y, et al. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma[J]. Urology, 2010, 75(3): 608-614.
[13]	Yao X, Qian C N, Zhang Z F, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications[J]. Clin Cancer Res, 2007, 13(1): 161-169.
[14]	Qian C N, Huang D, Wondergem B, et al. Complexity of tumor vasculature in clear cell renal cell carcinoma[J]. Cancer, 2009, 115(10 Suppl): 2282-2289.